
RECANTHIA

MOLECULAR INSIGHTS FOR CANCER R&D

Decode response. *Drive discovery.*

Recanthia develops transcriptomic research services to characterise treatment-response profiles, investigate biological mechanisms and support oncology R&D. First focus: triple-negative breast cancer.



Three research services

Characterise response

Profiles associated with response or resistance to a candidate treatment, with sensitivity analyses and validation leads.

Reveal mechanisms

Regulatory programmes, candidate targets and potential escape mechanisms, ranked by evidence, with suggested experiments.

Map populations

Frequency of profiles of interest in defined cohorts, with explicit transfer assumptions, to inform study design.

How a project works

1 Scoping → **2** Feasibility → **3** Analysis → **4** Interpretation → **5** Delivery

Your data

- Bulk RNA-seq with response or clinical metadata, or public cohorts
- Pseudonymised data only, under a confidentiality agreement
- Written analysis plan, robustness checks, reproducible code

For

Biotech, pharma, academic laboratories and translational research teams.

Availability

B2B research services planned for launch in 2027; first pilot partners welcome now. Project-based pricing.

Founded by Maxime Grember (CEO) and Nathan Horochowska Laneret (CTO), University of Lille.

Discuss your project
recanthia.com

contact@recanthia.com

Research stage. Results are research hypotheses, not diagnoses or validated clinical tests. Clinical applications are a future goal subject to validation.